Kimmtrak, also known as tepotinib, is an oral inhibitor of the c-MET tyrosine kinase receptor, prescribed for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. According to a study[1] published in the New England Journal of Medicine, the most common side effects of Kimmtrak include:
Fatigue (58% of patients)
Nausea (43%)
Diarrhea (42%)
Vomiting (38%)
Cough (35%)
Additionally, some patients experienced more serious side effects, such as:
Kidney problems (12% of patients)
Liver problems (6% of patients)
High levels of certain enzymes (9% of patients)
Abnormal heart rhythm (5% of patients)
The study also notes that some patients withdrew from the trial due to side effects, citing[2] a 15% incidence of discontinuation due to adverse events. The recommended dose of Kimmtrak is once daily, and patients should be monitored regularly for signs of side effects[3].
It is essential to consult a doctor or pharmacist for more information about potential side effects of Kimmrak and to discuss any concerns you may have.
Sources:
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa1908382
[2] https://www.fda.gov/drugs/information-drug-class/specific-drugs/tepotinib
[3] https://www.drugpatentwatch.com/meds/tepotinib
Please use the following as your bibliography:
1. https://www.nejm.org/doi/full/10.1056/NEJMoa1908382
2. https://www.fda.gov/drugs/information-drug-class/specific-drugs/tepotinib
3. https://www.drugpatentwatch.com/meds/tepotinib